Substance Use Disorder Treatment Market
By Treatment;
Detoxification, Counselling & Behavioral Therapy, Medication, and Support GroupBy Type;
Alcohol Abuse Treatment, Nicotine Abuse Treatment, and Drug Abuse TreatmentBy Substance Dependency;
Alcohol Use Disorder and Opioid Use DisorderBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Substance Use Disorder Treatment Market Overview
Substance Use Disorder Treatment Market (USD Million)
Substance Use Disorder Treatment Market was valued at USD 11,995.07 million in the year 2024. The size of this market is expected to increase to USD 17,646.75 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.7%.
Substance Use Disorder Treatment Market
*Market size in USD million
CAGR 5.7 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 5.7 % |
Market Size (2024) | USD 11,995.07 Million |
Market Size (2031) | USD 17,646.75 Million |
Market Concentration | Medium |
Report Pages | 316 |
Major Players
- Teva Pharmaceutical Industries Ltd
- Alkermes plc.
- Reckitt Benckiser Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- Pfizer, Inc.
- Cipla Limited
- Intas Biopharmaceuticals
- Indivior PLC and Opiant Pharmaceuticals
- Sahyog Clinic,
- Pear Therapeutics, Inc. and Sandoz,
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Substance Use Disorder Treatment Market
Fragmented - Highly competitive market without dominant players
The Substance Use Disorder Treatment Market is expanding as treatment centers and clinicians increasingly adopt comprehensive care models, integrating medication-assisted therapy and behavioral support in a single pathway. Nearly 65% of rehabilitation programs now utilize combined medication and psychotherapy approaches. This comprehensive model is advancing innovation and market expansion, supported by close collaboration between addiction specialists and pharmaceutical developers.
Enhanced Treatment Regimens with Digital Tools
Around 62% of treatment providers are enhancing regimens with features such as extended-release formulations, telehealth support, digital adherence tools, and integrated counseling modules. These are critical technological advancements that enhance patient engagement and treatment consistency. Joint efforts between behavioral health experts and tech innovators are enabling more effective interventions.
Data‑Driven Protocols Boosting Clinical Effectiveness
Coordinated programs between addiction clinics, mental health professionals, and research universities have led to a 59% rise in adoption of data-driven treatment plans and outcome tracking systems. These cross-functional collaborations ensure evidence-based protocols, personalized therapy adjustments, and monitoring strategies—leading to growth through unified care pathways.
Alliances Enhancing Access and Support Services
Approximately 63% of recent progression stems from strategic partnerships and brand licensing between treatment center networks, pharmaceutical firms, and digital health solution providers. These alliances broaden treatment accessibility, improve patient support infrastructure, and enhance continuity of care—fuelling consistent market expansion.
Substance Use Disorder Treatment Market Recent Developments
-
November 2022: Indivior PLC and Opiant Pharmaceuticals entered into an agreement to strengthen and expand Indivior's position in the market for addiction treatment.
-
November 2021: Sahyog Clinic, launched its new programs that include inpatient treatment of drug abuse and alcohol addiction, behavior and group therapy, substance abuse counseling, and detoxification from alcohol and drugs.
-
November 2021: Pear Therapeutics, Inc. and Sandoz, a division of Novartis, announced the commercial launch of reset for patients with substance use disorders (SUD). The first and only prescription digital therapeutic with FDA authorization is reSET.
Substance Use Disorder Treatment Market Segment Analysis
In this report, the Substance Use Disorder Treatment Market has been segmented by Treatment, Type, Substance Dependency, and Geography.
Substance Use Disorder Treatment Market, Segmentation by Treatment
The Substance Use Disorder Treatment Market has been segmented by Treatment into Detoxification, Counselling & Behavioral therapy and Medication & Support group.
Detoxification
In this phase patients undergo medically supervised withdrawal, often with medications to manage withdrawal symptoms and reduce health risks. This segment accounts for roughly 20–25% of the substance use disorder treatment market, serving as a critical gateway into comprehensive care.
Counselling & Behavioral Therapy
This sub‑segment includes cognitive‑behavioral therapy, motivational interviewing, and group counseling methods. Representing about 45–50% of the market, this approach focuses on behavior modification, emotional regulation, and developing long‑term recovery skills.
Medication & Support Group
This segment combines medication‑assisted treatment—such as methadone, buprenorphine, or naltrexone—with peer‑based
support groups
support groups like AA or NA. It makes up approximately 30–35% of the market and blends clinical efficacy with community‑driven relapse prevention.
Substance Use Disorder Treatment Market, Segmentation by Type
The Substance Use Disorder Treatment Market has been segmented by Alcohol Abuse Treatment, Nicotine Abuse Treatment, and Drug Abuse Treatment.
Alcohol Abuse Treatment
This segment delivers evidence‑based programs to combat alcohol dependence through a mix of behavioral therapy, medication‑assisted care, and relapse prevention. It captures around 40–45% of the global substance use disorder treatment market, driven by high incidence rates and growing access to rehabilitation services.
Nicotine Abuse Treatment
Focused on helping individuals quit tobacco and nicotine products, this sub‑segment employs behavioral counseling, nicotine replacement therapy, and FDA‑approved medications. Representing roughly 25–30% of the market, growth is fueled by public health campaigns and heightened awareness of smoking‑related health risks.
Drug Abuse Treatment
Covering interventions for illicit drugs and prescription misuse, this segment offers detoxification, medication‑assisted treatment, and behavioral counseling. Accounting for nearly 30–35% of the market, it is driven by the opioid crisis and the rise in synthetic drug abuse.
Substance Use Disorder Treatment Market, Segmentation by Substance Dependency
The Substance Use Disorder Treatment Market has been segmented by Alcohol Use Disorder and Opioid Use Disorder.
Alcohol Use Disorder
Treatment for alcohol dependence involves a combination of behavioral therapies, medication‑assisted care, and relapse prevention strategies. This segment holds roughly 45–50% of the global substance use disorder treatment market, driven by the high prevalence of alcohol misuse and greater access to rehabilitation programs. Integrated approaches often blend detoxification with ongoing psychological support for lasting recovery.
Opioid Use Disorder
Treatment for opioid dependence addresses both prescription opioid and illicit drug misuse using medication‑assisted treatment, behavioral counseling, and community support. Accounting for about 35–40% of the market, its rise is fueled by the opioid crisis and expanding public health initiatives. MAT options such as methadone, buprenorphine, and naltrexone are often paired with therapy to enhance recovery outcomes and reduce relapse.
Substance Use Disorder Treatment Market, Segmentation by Geography
In this report, the Substance Use Disorder Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Substance Use Disorder Treatment Market Share (%), by Geographical Region
North America
Leading the global market with about 40–45% share, this region benefits from advanced healthcare systems, high public awareness, and significant government funding. The U.S. remains the largest contributor due to elevated rates of opioid and alcohol misuse and a strong network of rehabilitation centers.
Europe
Holding around 25–28% of the market, Europe thrives on public health strategies and growing adoption of evidence‑based therapies. The UK, Germany, and France lead investments in prevention programs and integrated care models for substance abuse treatment.
Asia Pacific
With nearly 18–22% of the market, Asia Pacific is experiencing rapid growth due to rising substance misuse rates in urban areas. Government initiatives, mental health awareness campaigns, and new treatment facilities are driving expansion.
Middle East and Africa
Accounting for about 7–9% of the market, this region is steadily improving its addiction treatment infrastructure. Increased awareness, policy reforms, and regional collaborations are helping expand access to recovery services.
Latin America
Representing roughly 6–8% of the global market, Latin America’s growth is led by Brazil and Mexico. Public health campaigns, NGO‑led rehabilitation programs, and better treatment accessibility are supporting steady development.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Substance Use Disorder Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Personalized Care
- Holistic Approach
- Patient-Centered Care
-
Public Health Initiatives -Public health initiatives play a crucial role in addressing substance use disorder on a global scale. These initiatives are aimed at preventing substance abuse, promoting awareness, expanding access to treatment, and reducing the social and economic burden associated with addiction. Here are some key public health initiatives focused on the global substance use disorder treatment market:
Public health agencies and organizations implement education and prevention programs to raise awareness about the risks of substance abuse and promote healthy behaviors. These programs often target schools, communities, and workplaces, providing information about the harmful effects of drugs and alcohol and teaching skills to resist peer pressure and make healthy choices.
Public health initiatives advocate for evidence-based policies and regulations aimed at reducing substance abuse and its consequences. This includes advocating for stricter regulations on the marketing and sale of tobacco, alcohol, and other addictive substances, as well as policies to promote harm reduction strategies such as needle exchange programs and safe injection sites.
Public health efforts focus on improving access to substance use disorder treatment services, including pharmacological interventions, behavioral therapies, and support programs. Initiatives may involve integrating substance use disorder treatment into primary care settings, expanding insurance coverage for addiction treatment services, and establishing comprehensive treatment networks to ensure continuity of care.
Public health campaigns work to reduce the stigma associated with substance use disorder, which can prevent individuals from seeking help and accessing treatment. These campaigns aim to challenge negative stereotypes, promote empathy and understanding, and highlight the effectiveness of treatment and recovery.
Public health agencies collect data on substance abuse trends, treatment utilization, and outcomes to inform policy development, resource allocation, and program planning. Surveillance systems monitor indicators such as drug overdose deaths, emergency department visits, and substance use prevalence rates to identify emerging trends and prioritize interventions.
Public health initiatives on substance use disorder treatment often involve collaboration between governments, international organizations, non-governmental organizations (NGOs), and other stakeholders. These collaborations facilitate the exchange of best practices, capacity building, and resource sharing to address substance abuse on a global scale.
These and other public health initiatives, countries can work towards reducing the burden of substance use disorder, improving treatment outcomes, and promoting overall public health and well-being.
Restraints:
- Workforce Shortages
- Co-occurring Disorders
- Limited Evidence Base
-
Cultural and Linguistic Barriers -In the global substance use disorder treatment market, cultural and linguistic barriers present significant challenges that impact the delivery and effectiveness of treatment interventions. Cultural diversity plays a crucial role in shaping individuals' attitudes, beliefs, and behaviors towards substance use and treatment-seeking. Likewise, linguistic diversity adds another layer of complexity, affecting communication between patients and healthcare providers.
Cultural barriers encompass various factors such as societal norms, religious beliefs, and cultural practices surrounding substance use and mental health. Stigma associated with addiction may prevent individuals from seeking treatment due to fear of judgment or social ostracism within their communities. Moreover, cultural differences in the perception of mental health and addiction may influence help-seeking behaviors and treatment preferences.
Linguistic barriers pose challenges in accessing and understanding treatment information, communicating symptoms, and expressing emotional experiences effectively. Limited proficiency in the language spoken by healthcare providers may hinder individuals' ability to convey their needs accurately and understand treatment recommendations. This can lead to miscommunication, misunderstandings, and suboptimal treatment outcomes.
Cultural and linguistic barriers requires a multifaceted approach that recognizes and respects diversity while ensuring equitable access to culturally and linguistically appropriate care. This involves integrating cultural competence training into healthcare practices to enhance providers' understanding of diverse cultural backgrounds and their impact on treatment-seeking behaviors. Additionally, employing interpreters and utilizing translated materials can facilitate effective communication and improve patient-provider interactions.
Tailoring treatment approaches to align with cultural values and beliefs, such as incorporating traditional healing practices or involving family members in the treatment process, can enhance engagement and promote positive treatment outcomes. Moreover, fostering collaboration with community organizations and religious institutions can help reduce stigma, increase awareness, and facilitate access to treatment within culturally diverse populations.
Cultural and linguistic barriers, the global substance use disorder treatment market can strive towards providing inclusive and accessible care that meets the diverse needs of individuals struggling with addiction worldwide.
Opportunities:
- Holistic Wellness Programs
- Collaborative Care Models
- Workforce Development
-
Integration with Primary Care -The integration of substance use disorder (SUD) treatment with primary care is increasingly recognized as a crucial component of comprehensive healthcare delivery. By incorporating SUD treatment into primary care settings, healthcare providers can address addiction issues more effectively and holistically, improving patient outcomes and reducing healthcare disparities. This integration allows for early identification of substance use problems, timely intervention, and ongoing support within the familiar environment of primary care clinics.
Primary care providers play a pivotal role in the early detection and management of substance use disorders due to their frequent interactions with patients and their ability to establish long-term relationships. By integrating SUD screening, brief interventions, and referral to treatment (SBIRT) protocols into routine primary care visits, providers can identify at-risk individuals and initiate appropriate interventions before addiction progresses to severe stages.
Integrating SUD treatment with primary care facilitates a collaborative approach to patient care. Primary care teams can work alongside addiction specialists, mental health professionals, and social workers to develop personalized treatment plans that address the complex needs of individuals with substance use disorders. This multidisciplinary approach ensures that patients receive comprehensive care that encompasses medical, behavioral, and social aspects of addiction.
Integrating SUD treatment with primary care helps reduce stigma associated with seeking help for substance use disorders. By normalizing discussions about addiction and providing non-judgmental support within the primary care setting, individuals may feel more comfortable disclosing their struggles with substance use and seeking appropriate treatment.
Overall, the integration of SUD treatment with primary care holds great promise for improving access to evidence-based interventions, reducing healthcare costs, and enhancing the overall well-being of individuals affected by addiction. As healthcare systems continue to prioritize the integration of behavioral health services into primary care, the global substance use disorder treatment market is expected to witness further expansion and innovation in this area.
Competitive Landscape Analysis
Key players in Global Substance Use Disorder Treatment Market include.
- Teva Pharmaceutical Industries Ltd
- Alkermes plc.
- Reckitt Benckiser Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- Pfizer, Inc.
- Cipla Limited
- Intas Biopharmaceuticals
- Indivior PLC and Opiant Pharmaceuticals
- Sahyog Clinic,
- Pear Therapeutics, Inc. and Sandoz,
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Type
- Market Snapshot, By Substance Dependency
- Market Snapshot, By Region
- Substance Use Disorder Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Personalized Care
-
Holistic Approach
-
Patient-Centered Care
-
Public Health Initiatives
-
- Restraints
-
Workforce Shortages
-
Co-occurring Disorders
-
Limited Evidence Base
-
Cultural and Linguistic Barriers
-
- Opportunities
-
Holistic Wellness Programs
-
Collaborative Care Models
-
Workforce Development
-
Integration with Primary Care
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Substance Use Disorder Treatment Market, By Treatment, 2021 - 2031 (USD Million)
- Detoxification
- Counselling & Behavioral Therapy
- Medication
- Support Group
- Substance Use Disorder Treatment Market, By Type, 2021 - 2031 (USD Million)
- Alcohol Abuse Treatment
- Nicotine Abuse Treatment
- Drug Abuse Treatment
-
Substance Use Disorder Treatment Market, By Substance Dependency, 2021 - 2031 (USD Million)
-
Alcohol Use Disorder
-
Opioid Use Disorder
-
- Substance Use Disorder Treatment Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Substance Use Disorder Treatment Market, By Treatment, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd
- Alkermes plc.
- Reckitt Benckiser Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- Pfizer, Inc.
- Cipla Limited
- Intas Biopharmaceuticals
- Indivior PLC and Opiant Pharmaceuticals
- Sahyog Clinic,
- Pear Therapeutics, Inc. and Sandoz,
- Company Profiles
- Analyst Views
- Future Outlook of the Market